The world’s largest study of proteins circulating the human body will begin in the UK this month, with the aim of pinpointing ...

BC, MSCN has joined the Memory Clinic staff. Penny is board-certified in Family Practice with focused training in certain ...

ANK-700 is under clinical development by Anokion and currently in Phase I for Relapsing Remitting Multiple Sclerosis (RRMS).

Most MS treatments don't increase the risk for miscarriage or major birth defects when used during pregnancy, an analysis ...

The blood-brain barrier (BBB) is a major hurdle for the development of systemically delivered drugs targeting diseases of the central nervous system (CNS). Because of this barrier there is a huge ...

Memorial University researcher Michelle Ploughman says artificial intelligence can analyze health data in ways people can't, ...

The most-read stories published by Multiple Sclerosis News Today in 2024 focused on living with MS and news on disease risk factors.

Now, scientists at Stanford University have found that a faulty genetic molecule could be responsible for the immune system misidentifying healthy tissue as a threat. The breakthrough study, published ...

INR:8125. pkl final winners list Science sub-journal: Old drugs for multiple sclerosis can also treat brain cancer Zejing's new drug is approved for clinic ...

bumrah age China urgently needs new drugs for rare diseases from abroad: more than 10 drugs have been approved and many have submitted applications for listing Roche's multiple sclerosis drug Ocrevus ...

Multiple sclerosis (MS) is a disease marked by focal ... and the efficacy of our available treatments, remain inadequate. Here, we review the chief neuro-ophthalmologic abnormalities associated ...

Researchers from Harvard University have made a significant breakthrough in understanding multiple sclerosis (MS), a chronic ... EBV or creating antiviral drugs that specifically target the ...